Skip to content

Study · Randomized controlled trial · n = 22 · 1994

4 results

Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension.

Albillos A, Rossi I, Iborra J, Lledó JL, Calleja JL, Barrios C, García P, Escartín P

Journal of hepatology1 Jul 1994Cited by 49 (Europe PMC)

PMID7963427 (opens in a new tab)DOI10.1016/s0168-8278(94)80142-8 (opens in a new tab)PepBankPUB-07963427
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with cirrhosis, octreotide blunted the postprandial insulin increase observed with placebo.

    In plain wordsIn patients with cirrhosis, octreotide limited the insulin increase after eating compared with placebo.

    Peptide
    Octreotide
    Outcome
    DecreasePostprandial insulin
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    200 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Octreotide blunted the postprandial increase in serum insulin and glucagon levels observed in the placebo group.
    1 context sentence
    Summary · context
    Twenty-two patients with cirrhosis and portal hypertension were randomized to receive a mixed liquid meal (520 kcal) plus a single subcutaneous injection of either placebo or octreotide (200 micrograms).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with cirrhosis, octreotide blunted the postprandial glucagon increase observed with placebo.

    In plain wordsIn patients with cirrhosis, octreotide limited the glucagon increase after eating compared with placebo.

    Peptide
    Octreotide
    Outcome
    DecreasePostprandial glucagon
    Study

    n = 22

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    200 micrograms · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Octreotide blunted the postprandial increase in serum insulin and glucagon levels observed in the placebo group.
    1 context sentence
    Summary · context
    Twenty-two patients with cirrhosis and portal hypertension were randomized to receive a mixed liquid meal (520 kcal) plus a single subcutaneous injection of either placebo or octreotide (200 micrograms).
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with cirrhosis, the hepatic venous pressure gradient changed by -2.8 +/- 3.6% after eating with octreotide, without statistical significance.

    In plain wordsIn patients with cirrhosis given octreotide, eating caused no significant change in the hepatic venous pressure gradient.

    Peptide
    Octreotide
    Outcome
    No significant changeHepatic venous pressure gradient
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Liver
    Studied dose
    200 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Change in hepatic venous pressure gradient after meal
    −2.8%
    octreotide group, mean change, +/- 3.6, NS

    Source sentences

    Summary
    In contrast, in the octreotide group eating caused no significant change in the hepatic venous pressure gradient (-2.8 +/- 3.6%, NS), while hepatic flow was decreased (-6.08 +/- 5.4%, p < 0.05).
    1 context sentence
    Summary · context
    Twenty-two patients with cirrhosis and portal hypertension were randomized to receive a mixed liquid meal (520 kcal) plus a single subcutaneous injection of either placebo or octreotide (200 micrograms).
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with cirrhosis, hepatic flow decreased (-6.08 +/- 5.4%, p < 0.05) after eating with octreotide.

    In plain wordsIn patients with cirrhosis, liver blood flow decreased after eating with octreotide.

    Peptide
    Octreotide
    Outcome
    DecreaseHepatic blood flow
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Liver
    Studied dose
    200 micrograms · subcutaneousAs given in this study (human).

    Measurements

    Change in hepatic blood flow after meal
    −6.08%
    octreotide group, mean change, +/- 5.4, p < 0.05

    Source sentences

    Summary
    In contrast, in the octreotide group eating caused no significant change in the hepatic venous pressure gradient (-2.8 +/- 3.6%, NS), while hepatic flow was decreased (-6.08 +/- 5.4%, p < 0.05).
    1 context sentence
    Summary · context
    Twenty-two patients with cirrhosis and portal hypertension were randomized to receive a mixed liquid meal (520 kcal) plus a single subcutaneous injection of either placebo or octreotide (200 micrograms).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.